Kymera Therapeutics Inc (KYMR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -223,858 | -153,106 | -90,619 | -48,557 | -146,962 |
| Depreciation Amortization | -6,610 | -5,330 | -3,694 | -1,611 | -1,664 |
| Accounts receivable | 15,000 | 15,000 | 15,000 | 15,000 | -15,000 |
| Accounts payable and accrued liabilities | -307 | 198 | 106 | 75 | 2,038 |
| Other Working Capital | -23,970 | -20,419 | -19,448 | -6,316 | 2,682 |
| Other Operating Activity | 45,244 | 30,940 | 16,128 | 1,818 | 56,080 |
| Operating Cash Flow | $-194,501 | $-132,717 | $-82,527 | $-39,591 | $-102,826 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -12,838 | -11,902 | -12,091 | -7,402 | -34,480 |
| Purchase Of Investment | -901,226 | -822,804 | -526,860 | -422,704 | -189,151 |
| Sale Of Investment | 509,987 | 362,061 | 223,986 | 99,499 | 363,517 |
| Investing Cash Flow | $-404,077 | $-472,645 | $-314,965 | $-330,607 | $139,886 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -1,576 | -1,283 | -642 | -290 | -76 |
| Common Stock Issued | 610,427 | 607,369 | 355,810 | 354,046 | 4,268 |
| Financing Cash Flow | $608,851 | $606,086 | $355,168 | $353,756 | $4,192 |
| Beginning Cash Position | 115,777 | 115,777 | 115,777 | 115,777 | 74,525 |
| End Cash Position | 126,050 | 116,501 | 73,453 | 99,335 | 115,777 |
| Net Cash Flow | $10,273 | $724 | $-42,324 | $-16,442 | $41,252 |
| Free Cash Flow | |||||
| Operating Cash Flow | -194,501 | -132,717 | -82,527 | -39,591 | -102,826 |
| Capital Expenditure | -12,838 | -11,902 | -12,091 | -7,402 | -34,480 |
| Free Cash Flow | -207,339 | -144,619 | -94,618 | -46,993 | -137,306 |